Advinus Therapeutics CEO Rashmi Barbhaiya On Disruptive Innovation And India's R&D Edge: An Interview With PharmAsia News (Part 1 of 2)
This article was originally published in PharmAsia News
Advinus Therapeutics CEO Rashmi Barbhaiya is one of the most visible figures in today's pharmaceutical research in India. Beyond a deep knowledge of life sciences, he is famous for the daring - if not risky - moves that he made nine years ago, when he shifted from his top job in U.S.-based Bristol-Myers Squibb to head Ranbaxy's R&D team, and then spearheaded the research ambitions of India's biggest corporate conglomerate - The Tata group.
You may also be interested in...
Takeda looks to ride on Advinus’ broad early-stage pipeline while also generating new INDs.
The Indian venture is exploring financing options even as its lead molecule shows promise.
Jubilant will absorb the joint venture as Lilly steps down, despite enthusiasm for Indian partnerships.